Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

95.48 -1.18 (-1.22%)
Streaming Delayed Price Updated: 11:16 AM EDT, Jul 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 107,537
Open 96.76
Bid (Size) 95.30 (100)
Ask (Size) 95.61 (100)
Prev. Close 96.66
Today's Range 94.57 - 97.63
52wk Range 28.66 - 97.05
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know ↗
Atabak exercised options and immediately liquidated shares under a pre-established Rule 10b5-1 trading plan adopted in December 2025. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+149.9%
+149.9%
1 Month
+19.6%
+19.6%
3 Month
+111.8%
+111.8%
6 Month
+131.2%
+131.2%
1 Year
+39.6%
+39.6%

More News

Read More
News headline image
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound ↗
Via The Motley Fool
Topics Regulatory Compliance
Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup ↗
Via Chartmill
Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum ↗
Via Chartmill
News headline image
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Cash-Heavy Stocks with Questionable Fundamentals
Via StockStory
News headline image
3 High-Flying Stocks We Steer Clear Of
Via StockStory
News headline image
3 Unpopular Stocks We Steer Clear Of
Via StockStory
News headline image
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question
Via StockStory
News headline image
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
3 Reasons to Sell CORT and 1 Stock to Buy Instead
Via StockStory
News headline image
3 High-Flying Stocks We Think Twice About
Via StockStory
News headline image
Corcept (CORT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Corcept (CORT) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Corcept (CORT) Q1 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Corcept (CORT) Q2 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures
Via StockStory
News headline image
Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates
Via StockStory
News headline image
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Earnings: What To Look For From CORT
Via StockStory
Topics Artificial Intelligence

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 95.48
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 07/24/26 11:16 AM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 11.07B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.